国泰君安创新医药混合发起A(014157)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
14,171,201.13 |
-5,899,706.77 |
-8,294,137.67 |
-11,496,734.53 |
| 利息合计 |
40,262.43 |
60,195.35 |
25,247.12 |
60,047.00 |
| 其中：存款利息收入 |
38,280.37 |
60,195.35 |
25,247.12 |
60,047.00 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
3,573,136.80 |
-4,310,578.18 |
-4,629,287.21 |
-11,628,451.70 |
| 其中：股票投资收益 |
2,580,582.42 |
-5,967,721.87 |
-5,714,980.74 |
-12,860,918.17 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
992,554.38 |
1,657,143.69 |
1,085,693.53 |
1,232,466.47 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
10,426,447.48 |
-1,755,998.77 |
-3,702,241.78 |
-883,315.10 |
| 其他收入 |
131,354.42 |
106,674.83 |
12,144.20 |
954,985.27 |
| 费用 |
1,451,584.25 |
1,894,507.35 |
855,568.91 |
1,906,948.42 |
| 管理人报酬 |
1,072,264.28 |
1,455,417.06 |
668,528.21 |
1,501,185.07 |
| 基金托管费 |
178,710.77 |
242,569.52 |
111,421.42 |
250,197.56 |
| 销售服务费 |
123,549.05 |
44,775.05 |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
77,060.15 |
151,745.72 |
75,619.28 |
155,565.79 |
| 利润总额 |
12,719,616.88 |
-7,794,214.12 |
-9,149,706.58 |
-13,403,682.95 |
微信公众号
证券之星APP
基本资料
